Jonathan Avery, MD, director of addiction psychiatry, New York-Presbyterian Hospital, Weill Cornell Medical Center, explained why it’s important to diagnose and treat concurrent substance use disorders and mental illnesses at the same time.
Jonathan Avery, MD, director of addiction psychiatry, New York-Presbyterian Hospital, Weill Cornell Medical Center, explained why it’s important to diagnose and treat concurrent substance use disorders and mental illnesses at the same time.
Transcript
What can happen if a psychological disorder is treated but substance use is left undiagnosed or vice versa?
The big problem, I think, in American psychiatry or in medicine in general is that we tend to only treat 1 condition at a time, and often it’s the psychiatric condition and not the substance use disorder condition that gets treated. We think in an ideal world both should be treated at the same time, and if not, if you just treat the psychiatric condition and not the substance use, things aren’t going to get better, and similarly if you address the substance use without addressing the reason why they’re using, it sets the person up for failure. So you really have to address both at the same time if you want the person to get on the right track.
What are the dangers of misdiagnosing a psychiatric disorder when a substance use disorder is present?
Diagnosis can be very challenging when people are using substances. It’s unclear, as we were discussing, if the substance use leads to the mental illness, if the mental illness symptoms wouldn’t be there if they weren’t using a substance. These days, though, we sort of argue that things should be just kept simple, that if it looks like they have depressive symptoms, we don’t have to completely figure out if the substance use was related but they should all be addressed. So if it’s, say, someone who’s depressed and drinking a lot, it might be hard to tease out what started first—if the depression started first or the drinking started first—and our goal would be to recommend that you treat both. You give them medications for the substance, for the alcohol use, or the psychosocial treatment, and you give them meds and therapy if needed for the depression.
POSITIVE Trial Update on Patients With Breast Cancer Attempting Pregnancy
December 8th 2023At last year’s San Antonio Breast Cancer Symposium, POSITIVE trial primary outcome data were presented on breast cancer–free interval, with women who paused endocrine therapy to attempt pregnancy having a similarly small rate of recurrence vs external controls from the SOFT and TEXT trials: 8.9% vs 9.2%.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Refining Precision Prevention for Benign Breast Disease
December 7th 2023Many questions remain surrounding accurately classifying the risk of developing invasive breast cancer associated with the benign breast disease diagnoses of nonproliferative lesions and proliferative changes without atypia.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
ASH 2023 to Highlight Options in Care for Blood Diseases—for Those Who Have Access
December 7th 2023The 65th American Society of Hematology (ASH) Annual Meeting & Exposition, which runs Friday through Tuesday in the San Diego Convention Center, will showcase the growing number of treatment choices in blood cancers and disorders.
Read More
Race/Ethnicity May Influence Local Recurrence in DCIS, Adjuvant Treatment
December 6th 2023Disparities in 10-year local recurrence following breast-conserving surgery were seen among women with ductal carcinoma in situ (DCIS) treated over a nearly 4-decade span at Memorial Sloan Kettering Cancer Center, with Black women having the highest rate.
Read More